ABSTRACT
A novel series of erythromycin derivatives has been discovered with potent activity against key respiratory pathogens, including those resistant to erythromycin. These compounds are characterized by having an aryl group tethered to the C-6 position of the erythronolide skeleton. Extensive structural modification of the C-6 moiety led to the discovery of several promising compounds with potent activity against both mef- and erm-mediated resistant Streptoccoccus pneumoniae. Preliminary mechanistic studies indicated that the new macrolides are potent protein synthesis inhibitors, which interact with methylated ribosomes isolated from resistant organisms. In experimental animal models, these compounds exhibited excellent in vivo efficacy and balanced pharmacokinetic profiles.
Subject(s)
Anti-Bacterial Agents/chemical synthesis , Carbamates/chemical synthesis , Erythromycin/analogs & derivatives , Erythromycin/chemical synthesis , Ketolides , Protein Synthesis Inhibitors/chemical synthesis , Animals , Anti-Bacterial Agents/chemistry , Anti-Bacterial Agents/pharmacology , Carbamates/chemistry , Carbamates/pharmacology , Cell-Free System , Drug Resistance, Multiple , Erythromycin/chemistry , Erythromycin/pharmacology , Haemophilus influenzae/drug effects , Lung/microbiology , Mice , Models, Molecular , Protein Biosynthesis , Protein Synthesis Inhibitors/chemistry , Protein Synthesis Inhibitors/pharmacology , Rats , Respiratory Tract Infections/drug therapy , Respiratory Tract Infections/microbiology , Respiratory Tract Infections/mortality , Ribosomes/drug effects , Ribosomes/genetics , Staphylococcus aureus/drug effects , Streptococcus pneumoniae/drug effects , Streptococcus pneumoniae/ultrastructure , Streptococcus pyogenes/drug effects , Structure-Activity Relationship , Transcription, GeneticABSTRACT
ABT-773 is a novel ketolide effective against antibacterial-resistant respiratory tract pathogens. The pharmacokinetic profile of ABT-773 was studied in rats and consisted of a mean peak concentration in plasma of 1.07 microg/ml and an area under the concentration-time curve (AUC) of 12.03 microg. h/ml when the compound was delivered at a dose of 25 mg/kg of body weight. It concentrated in rat lung tissue, with a lung tissue-to-plasma ratio of 29 based on the AUC. In acute systemic infections in mice, ABT-773 showed efficacy against macrolide-susceptible strains of Staphylococcus aureus, Streptococcus pneumoniae, S. pyogenes, and Listeria monocytogenes. Additionally, ABT-773 improved the survival of mice infected with resistant S. pneumoniae containing either the ermB gene, the mefE gene, or altered penicillin binding protein genes. In a rat lung model of infection, ABT-773 demonstrated 50% effective doses lower than those of comparator macrolides when evaluated against the following strains of S. pneumoniae: a macrolide-lincosamide-streptogramin B-susceptible strain, an ermB strain, and an mefE strain. ABT-773 was also effective against Haemophilus influenzae lung infections in rats. Thus, ABT-773 may prove to be a useful new antibacterial agent for the treatment of respiratory tract infections.
Subject(s)
Bacterial Infections/drug therapy , Erythromycin/analogs & derivatives , Erythromycin/therapeutic use , Ketolides , Animals , Bacterial Infections/metabolism , Disease Models, Animal , Drug Resistance, Microbial , Erythromycin/pharmacokinetics , Female , Haemophilus Infections/drug therapy , Haemophilus Infections/metabolism , Haemophilus influenzae/drug effects , Listeriosis/drug therapy , Listeriosis/metabolism , Lung Diseases/drug therapy , Lung Diseases/metabolism , Lung Diseases/microbiology , Male , Mice , Rats , Rats, Sprague-Dawley , Respiratory Tract Diseases/drug therapy , Respiratory Tract Diseases/metabolism , Staphylococcal Infections/drug therapy , Staphylococcal Infections/metabolism , Streptococcal Infections/drug therapy , Streptococcal Infections/metabolism , Streptococcus pneumoniae/drug effects , Treatment OutcomeABSTRACT
The in vitro activities of ABT-773, erythromycin, clarithromycin, and azithromycin were compared. ABT-773 was the most active compound against macrolide-susceptible Streptococcus pneumoniae, Streptococcus pyogenes, Staphylococcus aureus, Staphylococcus epidermidis, Listeria monocytogenes, and Enterococcus spp. and multidrug-resistant Streptococcus pneumoniae. It also had good activity against gram-negative and atypical respiratory tract pathogens and Helicobacter pylori.
Subject(s)
Anti-Bacterial Agents/pharmacology , Erythromycin/analogs & derivatives , Erythromycin/pharmacology , Ketolides , Azithromycin/pharmacology , Clarithromycin/pharmacology , Drug Resistance, Multiple , Enterococcus/drug effects , Helicobacter pylori/drug effects , Humans , Microbial Sensitivity Tests , Staphylococcus/drug effects , Streptococcus/drug effects , Time FactorsABSTRACT
A novel class of 2-fluoro-6-O-propargyl-11,12-carbamate ketolide derivatives of erythromycin has been synthesized for antibacterial SAR studies. Replacement of the C2-hydrogen by a fluorine atom allows the synthesis of 6-O-propargylic ketones and electron-deficient 6-O-propargylic aromatic derivatives by preventing intramolecular C2-enolate Michael cyclization.
Subject(s)
Anti-Bacterial Agents/chemical synthesis , Erythromycin/analogs & derivatives , Anti-Bacterial Agents/chemistry , Crystallography, X-RayABSTRACT
A series of novel 6-O-substituted erythromycin A derivatives has been synthesized. Good in vitro antibacterial activity has been demonstrated for analogues incorporating a variety of structural features. The methodology disclosed is expected to find application in the design of future macrolide antibiotics that target the prevalent bacterial resistance problem.
Subject(s)
Anti-Infective Agents/chemical synthesis , Anti-Infective Agents/pharmacology , Erythromycin/analogs & derivatives , Erythromycin/chemical synthesis , Erythromycin/pharmacology , Microbial Sensitivity Tests , Structure-Activity RelationshipSubject(s)
Anti-Bacterial Agents/chemical synthesis , Haemophilus influenzae/drug effects , Macrolides/chemical synthesis , Staphylococcus/drug effects , Streptococcus/drug effects , Animals , Anti-Bacterial Agents/chemistry , Anti-Bacterial Agents/pharmacology , Drug Design , Drug Resistance, Microbial , Lung/microbiology , Lung Diseases/drug therapy , Macrolides/chemistry , Macrolides/pharmacology , Mice , Models, Molecular , Rats , Respiratory Tract Infections/microbiology , Staphylococcal Infections/drug therapy , Streptococcal Infections/drug therapy , Structure-Activity RelationshipABSTRACT
One major mechanism for resistance to macrolide antibiotics in Streptococcus pneumoniae is MLS (macrolide, lincosamide, and streptogramin B) resistance, manifested when the 23S rRNA is methylated by the product of an erm gene. This modification results in the decreased binding of all known macrolide, lincosamide, and streptogramin B antibiotics to the ribosome. More than 30 ermAM-containing clinical isolates of S. pneumoniae were examined in our lab and showed high-level resistance (MIC > or =128 microg/ml) to erythromycin, azithromycin, tylosin, clindamycin, and ketolide (macrolides that lack the cladinose sugar) TE-802. We found that the new generation of ketolides A965 and A088 displayed variable activity against the same group of resistant S. pneumoniae strains. To understand the basis of variability of the minimal inhibitory concentration (MIC) values of A965 and A088, we examined the effects of a series of macrolides and ketolides on the level of 23S rRNA methylation in five ermAM-containing resistant S. pneumoniae isolates. We show here that the basal levels of ribosomal methylation vary from strain to strain. The level of rRNA methylation can be strongly induced by erythromycin, azithromycin, and TE-802, resulting in high-level of resistance to these compounds. Ketolide A965 and A088, however, are weak inducers at sub-MIC drug concentrations, therefore showing variable activities in strains with differential methylation levels.
Subject(s)
Anti-Bacterial Agents/pharmacology , Macrolides , RNA, Ribosomal, 16S/metabolism , Streptococcus pneumoniae/drug effects , Virginiamycin/pharmacology , Drug Resistance, Microbial , Lincosamides , Methylation , Streptococcus pneumoniae/geneticsABSTRACT
C24-Deoxyascomycin was prepared in a two-step process from ascomycin and evaluated for its immunosuppressant activity relative to ascomycin and FK506. An intermediate in the synthetic pathway, Delta(23,24)-dehydroascomycin, was likewise evaluated. Despite lacking the hydrogen-bonding interactions associated with the C24-hydroxyl moiety of ascomycin, C24-deoxyascomycin was found to be equipotent to the parent compound both in its immunosuppressive potency and in its interaction with the immunophilin, FKBP12. Conversely, Delta(23,24)-dehydroascomycin which also lacks the same hydrogen-bonding interactions did not exhibit this potency. NMR studies were conducted on the FKBP12/C24-deoxyascomycin complex in an attempt to understand this phenomenon at the molecular level. The NMR structures of the complexes formed between FKBP12 and ascomcyin or C24-deoxyascomcyin were very similar, suggesting that hydrogen-bonding interactions with the C24 hydroxyl moiety are not important for complex formation.
Subject(s)
Immunophilins/metabolism , Immunosuppressive Agents/chemical synthesis , Peptidylprolyl Isomerase/metabolism , Tacrolimus/analogs & derivatives , Amino Acid Sequence , Animals , Humans , Hyperplasia , Immunophilins/chemistry , Immunophilins/genetics , Immunosuppressive Agents/chemistry , Immunosuppressive Agents/metabolism , Immunosuppressive Agents/pharmacology , Lymph Nodes/drug effects , Lymph Nodes/immunology , Lymph Nodes/pathology , Lymphocyte Culture Test, Mixed , Magnetic Resonance Spectroscopy , Male , Models, Molecular , Molecular Sequence Data , Nucleotidyltransferases/genetics , Peptidylprolyl Isomerase/chemistry , Peptidylprolyl Isomerase/genetics , Protein Binding , Rats , Rats, Inbred Lew , Rats, Sprague-Dawley , Recombinant Fusion Proteins/metabolism , Tacrolimus/chemical synthesis , Tacrolimus/chemistry , Tacrolimus/metabolism , Tacrolimus/pharmacology , Tacrolimus Binding ProteinsABSTRACT
The antibacterial 4H-4-oxoquinolizines were introduced recently to overcome bacterial resistance to fluoroquinolones. They exhibit potent antibacterial activity against Gram-positive, Gram-negative, and anaerobic organisms and are highly active against some quinolone-resistant bacteria including quinolone-resistant MRSA. Preliminary studies indicated that oxoquinolizines possess distinct activity and toxicity profiles as compared with their parent quinolones. In order to develop a potent antibacterial agent with the desired spectrum of activity, good tolerability, and balanced pharmacokinetic profile, we synthesized and evaluated a series of oxoquinolizines with various substituents at the C-8 position. Most compounds tested in this study demonstrated better activity against Gram-positive bacteria than ciprofloxacin and exhibited good susceptibility against ciprofloxacin- and methicillin-resistant S. aureus. While maintaining potent in vitro activity, several compounds showed improved in vivo efficacy over ABT-719 as indicated by the mouse protection test. As an example, the oral ED(50) values for the cis-3-amino-4-methylpiperidine analogue 3ss against S. aureus NCTC 10649M, S. pneumoniae ATCC 6303, and E. coli JUHL were 0. 8, 2.0, and 1.4 mg/kg, compared to 3.0, 10.0, and 8.3 mg/kg for ABT-719. The current study revealed that the steric and electronic environment, conformation, and absolute stereochemistry of the C-8 group are very important to the antibacterial profiles. Structural modifications of the C-8 group provide a useful means to improve the antibacterial activities, physicochemical properties, and pharmacokinetic profiles. Manipulation of the C-8 group also allows us to generate analogues with the desired spectrum of activity, such as analogues that are selective against respiratory pathogens.
Subject(s)
Anti-Bacterial Agents/chemical synthesis , Quinolizines/chemical synthesis , Animals , Anti-Bacterial Agents/chemistry , Anti-Bacterial Agents/pharmacology , Gram-Negative Bacteria/drug effects , Gram-Positive Bacteria/drug effects , Mice , Quinolizines/chemistry , Quinolizines/pharmacology , Stereoisomerism , Structure-Activity RelationshipABSTRACT
T lymphocytes play a critical part in inflammatory skin diseases but are targeted by available therapies that have only partial efficacy, significant side-effects, or both. Because psoriasis, atopic dermatitis, and allergic contact hypersensitivity are associated with T helper type 1 (Th1), T helper type 2 (Th2), or mixed Th1-Th2 cell subsets and cytokine types, respectively, there is a need for a better broad-based inhibitor. The macrolactam ascomycin analog, ABT-281, was found to inhibit potently T cell function across species and to inhibit expression of multiple cytokines in human peripheral blood leukocytes which have been found in human skin disease cells and tissues. These included immunoregulatory Th1 (interleukin-2 and interferon-gamma) and Th2 (interleukin-4 and interleukin-5) cytokines. ABT-281 was shown to have potent topical activity (ED50 = 0.6% in acetone/olive oil) in a stringent swine model of allergic contact hypersensitivity, but its potency was markedly reduced compared with ascomycin when administered systemically due to more rapid clearance. Topical application of 3% ABT-281 in acetone/olive oil over 25% of the body surface in swine resulted in undetectable blood levels. Compared with a wide potency range of topical corticosteroids in clinical formulations, 0.3% and 1% ABT-281 ointments profoundly inhibited dinitrochlorobenzene-induced contact hypersensitivity in the pig by 78% and 90%, respectively, whereas super-potent steroids such as clobetasol propionate only inhibited in the 50% range and mild to moderate potency steroids such as fluocinolone acetonide were inactive. The potent topical activity of ABT-281 in swine, its superior efficacy, its rapid systemic clearance following uptake into the bloodstream, and its ability to inhibit cytokine biosynthesis of both Th1 and Th2 cell subsets, suggests that it will have a broad therapeutic value in inflammatory skin diseases, including psoriasis, atopic dermatitis, and allergic contact dermatitis.
Subject(s)
Cytokines/antagonists & inhibitors , Dermatitis, Contact/drug therapy , Lactams/pharmacology , Th1 Cells/drug effects , Th2 Cells/drug effects , Administration, Topical , Animals , Anti-Inflammatory Agents/pharmacology , Anti-Inflammatory Agents/therapeutic use , Cell Division/drug effects , Cytokines/biosynthesis , Dermatitis, Contact/immunology , Disease Models, Animal , Dose-Response Relationship, Drug , Drug Administration Routes , Drug Evaluation, Preclinical , Female , Guinea Pigs , Humans , Lactams/metabolism , Lactams/therapeutic use , Male , Mice , Rats , Swine , Tacrolimus/analogs & derivatives , Tacrolimus/pharmacology , Tacrolimus/therapeutic useABSTRACT
The potent immunosuppressant ascomycin (1b) was selectively alkylated at the C-32 carbinol, thus providing esters and amides of 32-ascomycinyloxyacetic acid (4, AOAA). These compounds present structural variation at the FKBP/calcineurin interface. While the native carboxylic acid 4 shows no activity in vitro, esters and simple amides of 4 exhibit potent immunosuppression in the human MLR assay. Moreover, amides show inhibitory activity in the rat popliteal lymph node hyperplasia assay. Surprisingly, FKBP binding was weakened by several orders of magnitude when secondary hydrophobic aryl amides of 4 were tested, while maintaining potent immunosuppressive efficacy in vitro.
Subject(s)
Carrier Proteins/metabolism , DNA-Binding Proteins/metabolism , Heat-Shock Proteins/metabolism , Immunosuppressive Agents/pharmacology , Tacrolimus/analogs & derivatives , Animals , Calcineurin/metabolism , Humans , Hyperplasia , Immunosuppressive Agents/chemical synthesis , Immunosuppressive Agents/chemistry , Immunosuppressive Agents/metabolism , Lymph Nodes/drug effects , Lymph Nodes/pathology , Lymphocyte Culture Test, Mixed , Rats , Rats, Inbred Lew , Structure-Activity Relationship , Tacrolimus/chemical synthesis , Tacrolimus/chemistry , Tacrolimus/metabolism , Tacrolimus/pharmacology , Tacrolimus Binding ProteinsABSTRACT
A series of 3-descladinosyl-2,3-anhydro-6-O-methylerythromycin A 11, 12-carbamate analogues have been synthesized and evaluated for antibacterial activity. These compounds were found to be potent antibacterial agents against Gram-positive organisms in vitro, many having MIC values below 1 microg/mL for the macrolide-susceptible Staphylococcus aureus, Streptococcus pyogenes, and Streptococcus pneumoniae, as well as improved activity compared to erythromycin A against the inducibly MLS (macrolide, lincosamide, and streptogramin B)-resistant organisms. Structure-activity studies revealed that arylalkyl carbamates with two and four carbon atoms between the aromatic moiety and carbamate nitrogen have the best in vitro activity. All of the C-10 epi analogues evaluated were found to have substantially less activity than the corresponding natural C-10 isomer. Several analogues demonstrated moderate antibacterial activity against the constitutively resistant S.aureus A-5278, S. pneumoniae5979, and S.pyogenes 930. However, despite potent in vitro activity, these analogues showed only moderate in vivo activity in mouse protection studies.
Subject(s)
Anti-Bacterial Agents , Carbamates , Erythromycin , Animals , Anti-Bacterial Agents/chemical synthesis , Anti-Bacterial Agents/chemistry , Anti-Bacterial Agents/pharmacology , Carbamates/chemical synthesis , Carbamates/chemistry , Carbamates/pharmacology , Clarithromycin/chemistry , Clarithromycin/pharmacology , Colony Count, Microbial , Drug Evaluation, Preclinical , Drug Resistance, Microbial , Drug Resistance, Multiple , Erythromycin/analogs & derivatives , Erythromycin/chemical synthesis , Erythromycin/chemistry , Erythromycin/pharmacology , Haemophilus influenzae/drug effects , Lincosamides , Macrolides/pharmacology , Mice , Molecular Conformation , Pneumococcal Infections/prevention & control , Staphylococcal Infections/prevention & control , Staphylococcus aureus/drug effects , Streptococcus pneumoniae/drug effects , Streptococcus pyogenes/drug effects , Structure-Activity Relationship , Virginiamycin/pharmacologyABSTRACT
A series of 3-descladinosyl-2,3-anhydro-6-O-methylerythromycin A 11, 12-cyclic carbazate analogues was prepared and evaluated for antibacterial activity. These 2,3-anhydro macrolides were found to be potent antibacterial agents in vitro against macrolide-susceptible organisms including Staphylococcus aureus 6538P, Streptococcus pyogenes EES61, and Streptococcuspneumoniae ATCC6303. These compounds were also very active against some organisms that show macrolide resistance (S. aureus A5177, S. pyogenes PIU2584, and S. pneumoniae 5649). The compounds generally showed poor activity against organisms with constitutive MLS resistance. Selected compounds were evaluated in vivo in mouse protection studies. Although most of the compounds tested in vivo showed poor efficacy, two compounds, 38 and 57, were more active than clarithromycin against S. pneumoniae ATCC6303.
Subject(s)
Anti-Bacterial Agents , Erythromycin/analogs & derivatives , Animals , Anti-Bacterial Agents/chemical synthesis , Anti-Bacterial Agents/chemistry , Anti-Bacterial Agents/pharmacology , Clarithromycin/pharmacology , Drug Evaluation, Preclinical , Drug Resistance, Microbial , Drug Resistance, Multiple , Erythromycin/chemical synthesis , Erythromycin/chemistry , Erythromycin/pharmacology , Lincosamides , Macrolides/pharmacology , Mice , Pneumococcal Infections/prevention & control , Staphylococcal Infections/prevention & control , Staphylococcus aureus/drug effects , Streptococcus pneumoniae/drug effects , Streptococcus pyogenes/drug effects , Structure-Activity Relationship , Virginiamycin/pharmacologyABSTRACT
Drug therapy for the major inflammatory skin diseases, which include atopic dermatitis, psoriasis and allergic contact dermatitis, is often inadequate due to poor efficacy, toxicity, or both. Much research has focused on the macrolactam T cell inhibitors as a promising new class of agents for immunotherapy, and medicinal chemistry efforts to design novel ascomycin analogs have produced clinically promising agents. A synthetic program to modify the ascomycin nucleus to alter its physicochemical properties and promote systemic clearance is described. A biologic screening strategy to identify analogs with reduced systemic activity and rapid pharmacokinetic elimination led to identification of the clinical candidate, ABT-281. A swine contact hypersensitivity model was used as a stringent indicator of skin penetration as human doses of topical corticosteroids produced inhibition only in the 50% range and ED50 values were 100-fold less potent than in rat. Also, cyclosporine was confirmed to be topically inactive in swine, as seen in human. ABT-281 had topical potency equal to tacrolimus (FK506) despite a severalfold lower potency for inhibiting swine T cells in vitro, consistent with superior skin penetration. ABT-281 was found to have a shorter duration of action after i.v. dosing in monkeys using an ex vivo whole blood IL-2 production assay. Systemic potency was reduced by 30-fold or more in rat popliteal lymph node hyperplasia and contact hypersensitivity assays. Following i.v. or i.p. administration in the swine contact hypersensitivity model, ABT-281 was 19- and 61-fold less potent, respectively, than FK506. Pharmacokinetic studies showed that ABT-281 had a shorter half life and higher rate of clearance than FK506 in all three species. The potent topical activity and reduced systemic exposure of ABT-281 may thus provide both efficacy and a greater margin of safety for topical therapy of skin diseases.
Subject(s)
Dermatitis/drug therapy , Immunosuppressive Agents/therapeutic use , Inflammation/drug therapy , Skin Diseases/drug therapy , Tacrolimus/analogs & derivatives , Tacrolimus/pharmacology , Administration, Topical , Animals , Anti-Inflammatory Agents/therapeutic use , Cyclosporine/pharmacology , Drug Design , Humans , Immunosuppressive Agents/adverse effects , Interleukin-2/metabolism , Skin Diseases/immunology , T-Lymphocytes/drug effects , Tacrolimus/adverse effects , Tacrolimus/therapeutic useABSTRACT
The 11,12-cyclic carbazate of 3-keto-6-O-methylerythromycin A (4) was prepared. This compound shows in vitro antibacterial activity comparable to erythromycin A (1) against erythromycin-susceptible organisms and increased activity against some erythromycin-resistant organisms. Using 4 as a lead, a series of analogues was prepared by acylation or alkylation of the carbazate nitrogen. Several of the N-alkylated derivatives showed dramatically improved antibacterial activity against both susceptible and resistant organisms as compared to erythromycin A.
Subject(s)
Anti-Bacterial Agents/chemical synthesis , Anti-Bacterial Agents/pharmacology , Erythromycin/pharmacology , Ketolides , Anti-Bacterial Agents/chemistry , Erythromycin/analogs & derivatives , Erythromycin/chemical synthesis , Erythromycin/chemistry , Microbial Sensitivity Tests , Molecular Structure , Structure-Activity RelationshipSubject(s)
Amino Acid Isomerases/pharmacology , Anti-Bacterial Agents/pharmacology , Calmodulin-Binding Proteins/metabolism , Calmodulin-Binding Proteins/physiology , Carrier Proteins/pharmacology , Cyclosporine/pharmacology , Lymphocytes/immunology , Phosphoprotein Phosphatases/metabolism , Phosphoprotein Phosphatases/physiology , Tacrolimus/pharmacology , Amino Acid Sequence , Calcineurin , Calmodulin-Binding Proteins/antagonists & inhibitors , Dose-Response Relationship, Drug , Humans , Kinetics , Lactams , Lymphocyte Culture Test, Mixed , Lymphocytes/drug effects , Lymphocytes/metabolism , Molecular Sequence Data , Peptidylprolyl Isomerase , Phosphopeptides/chemical synthesis , Phosphopeptides/metabolism , Phosphoprotein Phosphatases/antagonists & inhibitors , Recombinant Fusion Proteins/pharmacology , Substrate Specificity , Tacrolimus Binding ProteinsABSTRACT
The synthesis and structure-activity relationships of C-terminal octapeptide analogues of anaphylatoxin C5a have been studied. The introduction of hydrophobic amino acids into the N-acetylated native octapeptide (N-Ac-His-Lys-Asp-Met-Gln-Leu-Gly-Arg-OH) (1) has led to an analogue with 100 times more activity than the native octapeptide in inhibiting the binding of 125I-labeled anaphylatoxin C5a to human neutrophil membrane receptors. The observed apparent binding Ki's for the compounds (8-10) are in the range of 1-3 microM, and they possess nearly full agonist activity, despite the fact that these analogues are one-eighth or -ninth the size of the natural ligand anaphylatoxin C5a.
Subject(s)
Complement C5a/metabolism , Neutrophils/immunology , Receptors, Complement/metabolism , Amino Acid Sequence , Animals , Binding, Competitive , Chemotaxis, Leukocyte/drug effects , Humans , In Vitro Techniques , Molecular Sequence Data , Neutrophils/drug effects , Oligopeptides/metabolism , Oligopeptides/pharmacology , Receptor, Anaphylatoxin C5a , Sequence Homology, Nucleic Acid , Structure-Activity RelationshipSubject(s)
Complement C5a/metabolism , Receptors, Complement/metabolism , Amino Acid Sequence , Animals , Capillary Permeability/drug effects , Complement C5a/chemical synthesis , Complement C5a/chemistry , Guinea Pigs , Histidine , Humans , In Vitro Techniques , Molecular Sequence Data , Neutrophils/immunology , Peptide Fragments/chemical synthesis , Peptide Fragments/metabolism , Receptor, Anaphylatoxin C5a , Receptors, Complement/antagonists & inhibitors , Skin/blood supply , Structure-Activity RelationshipABSTRACT
A number of C5a modifications were tested to determine effects on receptor binding to polymorphonuclear leukocyte (PMNL) membrane receptors and triggering of PMNL chemokinesis and myeloperoxidase (MPO) release. Site-directed mutagenesis was used to probe relationships of key C-terminal residues, and suggested a role for additional sites, particularly Lys19-20. A synthetic peptide based on C5a 19-30, weakly inhibited C5a binding. Potency of the C-terminal octapeptide, a full agonist, was markedly improved by a single Phe substitution for His67, and a Phe point mutation at this site was shown to enhance activity of the full recombinant protein.
Subject(s)
Complement C5a/metabolism , Neutrophils/metabolism , Receptors, Cell Surface/metabolism , Cells, Cultured , Humans , Recombinant Proteins/metabolism , Structure-Activity RelationshipABSTRACT
The pentapeptide Ser-Asn-Val-Phe-Ala-OBzl has been identified as the smallest inhibitory peptide of myosin light chain kinase (MLCK) derived from the primary sequence of the light chain phosphorylation site. The specific contributions of individual amino acid side chains and backbone elements of this pentapeptide toward the stabilization of the enzyme-inhibitor (E-I) complex have been evaluated. The potency of these peptides as inhibitors of MLCK has been enhanced by the incorporation of synthetic nonnatural amino acids into the sequence. Finally, it has been demonstrated that these peptide sequences could be converted into pseudopeptides with synthetic nonpeptide subunits designed to mimic peptide bonds, and that certain pseudopeptides retained the high-affinity inhibition of the parent pentapeptides.